Routine, comprehensive molecular characterization of patient tumours has the potential to accelerate therapeutic advances and inform cancer biology. Here, we describe insights from the implementation of an enterprise-wide, prospective clinical sequencing strategy at an academic cancer centre.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Precision medicine: affording the successes of science
npj Precision Oncology Open Access 04 January 2023
-
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Experimental Hematology & Oncology Open Access 31 October 2022
-
A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer
BMC Genomics Open Access 23 October 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017).
Mandelker, D. et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA versus guideline-based germline testing. JAMA 318, 825–835 (2017).
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
Hyman, D. M. et al. AKT inhibition in solid tumors with AKT1 mutations. J. Clin. Oncol. 35, 2251–2259 (2017).
Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189–194 (2018).
Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374–382 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.B.S. has served in a consulting or advisory role to Loxo Oncology and Pfizer. D.M.H. has served in a consulting or advisory role to Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer and Genentech, and received research funding from AstraZeneca, Puma Biotechnology and Loxo Oncology. M.L.C. and M.F.B. declare no competing interests.
Rights and permissions
About this article
Cite this article
Cheng, M.L., Berger, M.F., Hyman, D.M. et al. Clinical tumour sequencing for precision oncology: time for a universal strategy. Nat Rev Cancer 18, 527–528 (2018). https://doi.org/10.1038/s41568-018-0043-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-018-0043-2
This article is cited by
-
An approach for improvement of the accuracy of cancer gene panel testing
International Journal of Clinical Oncology (2024)
-
Precision medicine: affording the successes of science
npj Precision Oncology (2023)
-
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Experimental Hematology & Oncology (2022)
-
Genomic profiling in oncology clinical practice
Clinical and Translational Oncology (2020)
-
Pan-cancer image-based detection of clinically actionable genetic alterations
Nature Cancer (2020)
